Articles tagged with Ovarian Cancer
Researchers at the Mayo Clinic found that surgical removal of both ovaries in women under 43 increases their risk of developing Parkinson's disease and parkinsonism. The study used health record data from the Rochester Epidemiology Project to analyze over 2,750 women who underwent bilateral oophorectomy.
Researchers from Swansea University and Université Grenoble Alpes demonstrate the effectiveness of selenium nanoparticles in killing ovarian cancer cell models. The study reveals a novel biological mechanism underlying the anti-cancer effect, involving histone methylatransferases and epigenetic processes.
Researchers discovered that quiescent ovarian cancer cells secrete follistatin, which induces resistance in neighboring cells and worsens survival rates. Targeting this protein may improve chemotherapy response and boost survival in patients with aggressive ovarian cancer.
A new study found that women with BRCA1 or BRCA2 mutations have a cumulative risk of 49% developing any type of cancer after age 50. Risk-reducing surgeries like mastectomies and BSOs can lower this risk, but many women opt out despite elevated risk. Genetic testing is crucial for accurate risk assessment and personalized care.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
Researchers at Karolinska Institutet have developed a new type of CAR T-cell therapy that effectively attacks and destroys ovarian cancer cells, significantly prolonging the lives of mice with the disease. The treatment has shown promising results in reducing tumor size and curing several mice.
A new study suggests that higher consumption of ultra-processed foods may be linked to an increased risk of developing and dying from cancer. The study found that each 10% increase in ultra-processed food consumption was associated with a 2% increase in cancer incidence, as well as a 6% increase in mortality from cancer.
A study suggests that loyalty card data on over-the-counter medicine purchases could help spot ovarian cancer cases earlier. Women with ovarian cancer were found to buy more pain and indigestion medications before diagnosis, often up to 8 months prior. This could lead to improved survival rates if symptoms are picked up earlier.
A study found a link between pain and indigestion medication purchases and ovarian cancer diagnoses, suggesting earlier symptom recognition. The research suggests that loyalty card data can be used to identify potential ovarian cancer cases.
A new study suggests that acupressure before surgery can reduce anxiety, while acupuncture during surgery may provide additional relief from severe pain. The research found that patients who received these treatments had better recovery scores and lower levels of pain and anxiety compared to those who received standard care.
A study by Mayo Clinic researchers found a specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer. The discovery strengthens evidence that the bacterial component of the microbiome is an important indicator for early detection, diagnosis, and prognosis of ovarian cancer.
A new genetic test has been developed to identify ovarian cancer patients who benefit from PARP inhibitors, a treatment option with significant improvements in prognosis. The test has been optimized for the Finnish population and is clinically approved, allowing for targeted treatment and reduced adverse effects.
A new software developed by researchers at Cold Spring Harbor Laboratory can accurately infers continental ancestry from tumor DNA and RNA. This technology has the potential to lead to more targeted and personalized cancer treatments by identifying genetic connections between cancer and race or ethnicity.
Researchers at Memorial Sloan Kettering Cancer Center have discovered several mechanisms of immune escape that contribute to ovarian cancer's resistance to immunotherapy. The study reveals that ovarian tumors develop new mutations to evade the immune system as they spread, making it challenging to identify a marker for predicting respo...
The National Cancer Institute awards $10.5 million to USC's Division of Biostatistics to develop statistical methods for uncovering new risk factors associated with cancer by integrating large volumes of health, genomic, and exposure data. The project aims to provide new insights into complex biological processes and discoveries of nov...
Researchers analyzed genetic data from 233 patients with ovarian cancer and found that precise localization of BRCA gene mutations is crucial for effective treatment. The study suggests that PARP inhibitors can be highly effective in patients with mutations in the DNA-binding domain, leading to improved overall survival rates.
In a recent study, researchers targeted the POL theta enzyme to inhibit DNA production in cancer cells. The approach represents a new method for developing specific therapies for patients with BRCA1 mutations.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A study of 11,945 people found that those with type 2 diabetes are more likely to be diagnosed with advanced cancer if the condition is not screened for routinely. Researchers identified a 26% increased risk of metastasis in patients with pre-existing type 2 diabetes.
A new study found that BRCA1/2 mutation-associated cancers have specific features that contribute to their high risk of recurrence, including changes in the BRCA2 protein's messenger-RNA molecule. The researchers identified multiple novel markers of therapeutic resistance, highlighting the importance of tumor profiling at treatment time.
A new study published in JNCCN found significant disparities in ovarian cancer treatment based on patient race, ability to pay, and healthcare access. Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment compared to White patients.
Research suggests that antibiotics used in ovarian cancer treatment can accelerate cancer progression and lower survival rates. Reintroducing healthy gut bacteria may slow down cancer growth and restore sensitivity to chemotherapy.
A specialized triage algorithm, ROCA test, enables earlier stage diagnosis in women deferring preventive surgery, saving NHS costs. The approach results in fewer major surgical interventions and lower risk of wider disease spread.
Two new discoveries led by Cedars-Sinai Cancer investigators improve understanding of ovarian cancer's development and suggest personalized therapeutic approaches. They identified four new genetic regions linked to increased ovarian cancer risk and found that some tumors may develop resistance to chemotherapy from an early stage.
A Phase Ib clinical trial found that sequential administration of PARP inhibitor olaparib and WEE1 inhibitor adavosertib is safe and well-tolerated, with promising signs of anti-tumor activity in patients with advanced cancers driven by DNA damage response mutations. The combination showed durable responses in patients with resistant c...
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
A meta-analysis of 410 articles from 68 countries found that patients in lower-income countries take up to four times longer to initiate care for cancer treatment. Cancers causing non-specific symptoms, such as myeloma and colorectal cancer, typically take the longest to diagnose.
A new potential antitumor drug, TRIP, causes rapid protein aggregation, hyperactivating the unfolded protein response and leading to programmed cell death in ovarian cancer cells. The Fe-S cluster biogenesis factor NUBP2 is identified as the probable starting point for the cellular processes triggered by TRIP.
A global study found that early-stage mucinous ovarian cancer patients with an infiltrative pattern of invasion have poorer survival chances. This discovery could lead to more targeted treatment strategies for these patients. Researchers hope to develop targeted drugs and align treatment guidelines worldwide.
MUSC researcher Joe Delaney, Ph.D., is awarded $453,000 to investigate aneuploidy in ovarian cancer. His project aims to target the cadmium response pathway and develop a new type of cancer drug for patients.
Researchers developed a computational platform to identify metabolic vulnerabilities in ovarian cancer genes, suggesting opportunities for targeted therapies. The study found that certain genetic alterations can create vulnerabilities in cancer cell metabolism, which can be exploited to selectively kill cancer cells.
Researchers at Oregon State University have developed a promising messenger RNA therapy for ovarian cancer, which also shows promise in treating cachexia, a muscle-wasting condition associated with cancer. The treatment uses lipid nanoparticles to deliver mRNA that triggers the production of the follistatin protein within cancer clusters.
Researchers at Cleveland Clinic link HSD3B1 genotype to higher risk of type 2 endometrial cancer, which is more aggressive and has lower survival rates than type 1. The study builds on previous associations with breast and prostate cancer, suggesting the gene could serve as a biomarker for certain subtypes.
A new study has successfully predicted ovarian cancer in patients with a pelvic mass using a simple blood test. The liquid biopsy technology captures circulating tumor cells, allowing for genetic analysis in just a couple of hours, which can help diagnose the disease earlier.
Rice University researchers have developed a treatment combining drug factory implants producing interleukin-2 with checkpoint inhibitors to eradicate advanced-stage mesothelioma tumors in mice. The treatment resulted in complete tumor destruction in all seven treated mice, offering a promising approach to this aggressive lung cancer.
A new study published in the Journal of Clinical Oncology found that frequent aspirin use is linked with a 13% reduced risk of ovarian cancer in individuals with multiple risk factors. Aspirin benefitted most subgroups, including those with endometriosis and obesity.
Researchers discover G6PD's pivotal role in activating pentose phosphate pathway to counter oxidative stress, leading to increased cell death and tumor shrinkage. Ovarian cancer cells' reliance on fatty acid metabolism fuels oxidative compound production, which can be offset by G6PD inhibition.
A phase III clinical trial found that taxane maintenance therapy did not significantly improve overall survival for women with advanced ovarian, peritoneal, and tubal cancers. The treatment resulted in significant gastrointestinal and neurological adverse events.
Wistar scientists have identified a novel therapeutic approach that inhibits the gene KDM5A, which improves immune cell infiltration and attack on tumors. This approach has shown promising results in both in vitro and in vivo studies, including reduced tumor burden and improved survival rates in mice with ovarian cancer.
Researchers from Bern and Geneva universities will receive $878,000 in funding to investigate mechanisms of resistance to PARPi inhibitors in BRCA-mutated ovarian cancer. The goal is to develop new targeted therapies to improve survival rates for patients with drug-resistant ovarian cancer.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
New research suggests vitamin D can effectively prevent ovarian cancer by restoring the body's natural defenses. The study found that vitamin D counteracts the process of peritoneal metastasis, which allows cancer cells to spread, and strengthens the barrier effect of mesothelial cells.
A new nanosensor platform uses machine learning to analyze spectral signatures of carbon nanotubes for early detection of ovarian cancer. The approach detects biomarkers and recognizes the cancer itself, offering a promising alternative to traditional methods.
Researchers identified OR2H1 as an effective target for CAR T cells in solid tumors, inhibiting growth in lung and ovarian cancer. The study suggests that targeting this protein could lead to the development of new CAR T therapies for a wide variety of patients with solid tumors.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers discovered that sialylation of the epidermal growth factor receptor modulates cell mechanics and enhances cancer cell invasion. ST6Gal-I, an enzyme that adds sialic acid to EGFR, plays a key role in tumor progression and metastasis.
Researchers at Gladstone Institutes and UC San Francisco have developed a comprehensive rule book for designing therapeutic cells with improved specificity and safety. The new receptor system, dubbed SNIPRs, is small enough for cost-effective engineering into human cells and can detect and respond to even small amounts of its target. T...
Researchers at Moffitt Cancer Center have discovered that tissue-resident memory T cells are crucial for recognizing tumor cells in ovarian cancer. These T cells arise from circulating T cells and undergo a differentiation process to target cancer cells, providing a potential roadmap for improved immunotherapy options.
Researchers developed a bioinformatics platform called REFLECT to predict optimal combination therapies based on co-occurring tumor alterations. The tool selected combinations that resulted in improved patient outcomes across pre-clinical and clinical studies, leading to increased durable responses.
Researchers at UC San Diego found that ovarian cancer tumors activate FAK protein to regulate CD155 expression, creating a shield against immune detection and evading treatment. New molecular targets may boost immune response and lead to new combinatorial strategies for this disease.
A new study reveals funding for fertility preservation policies varies across the UK, with Scotland offering the most inclusive approach. The study highlights the need for standardization of policies to ensure equal access to care for patients.
The Victoria's Secret Global Fund for Women's Cancers has awarded five female researchers for their groundbreaking work on breast and gynecologic cancers. The recipients will receive a $100,000 honorarium and be invited to participate in a broader women's cancers grant program.
The ATHENA-MONO trial shows significant improvements in progression-free survival for patients with advanced ovarian cancer treated with Rubraca as maintenance therapy. Benefit was observed across all patients, including those with homologous recombination deficiency and BRCA mutant tumors.
Researchers create detailed 'atlas' of fallopian tube cells to better understand fertility and disease. The study identifies 10 epithelial cell subtypes and reveals new insights into ovarian cancer origins.
A new study published in Radiology has found that ultrasound images can effectively classify adnexal lesions into classic and non-classic categories, with a sensitivity of 92.5% for diagnosing malignancy. The classic versus non-classic approach could help radiologists quickly assess lesions and avoid unnecessary surgery.
The study found that homologous recombination repair mutant type (HRRmt) was prognostic of progression-free survival and predictive for olaparib activity in women with recurrent platinum-sensitive ovarian cancer. Patients with BRCA mutations showed clinically significant activity when treated with experimental drugs.
Researchers discovered that ovarian cancer tumors evade immune attack by redirecting tryptophan breakdown to the serotonin pathway, increasing NAD+ levels. Blocking this pathway with IDO1 inhibitors can be ineffective due to the adaptation of tumor microenvironments.
Researchers at University of Queensland have identified a genetic basis for the increased risk of epithelial ovarian cancer in women with endometriosis. The study found genes that could be targeted to treat both conditions, increasing understanding and treatment options.
A new study found that nearly one-third of older adult female survivors of colorectal, endometrial, and ovarian cancer experience quality-of-life-impacting challenges with physical activity due to chronic lower extremity lymphedema. The researchers urge the medical community to include regular lymphedema assessments in survivorship care.
A meta-analysis of over 3,000 studies found that women with one ovary have a 30% lower chance of becoming pregnant and giving birth after IVF. The study suggests that surgical removal of an ovary has an adverse effect on fertility.